NSABP DP-1
Select A Category

NSABP DP-1

NSABP Biospecimen Discovery Project

Protocol Chair :Matthew Ellis, MB, BChir, PhD

Protocol Officer: Samuel Jacobs, MD

Primary Objective:The primary aim of this study is to determine the feasibility of comprehensive tumor 'omics profiling in patients receiving an upfront regimen containing a taxane plus HER (antibody[ies] or

TKI)-based combination.

Patient Population: Operable and Locally Advanced HER2-Positive Breast Cancer

Target Accrual: 50 patients

Status: Recruiting participants

ClinicalTrials.gov IdentifierNCT01850628